Table 2.
Age-standardised net survival of patients diagnosed with colorectal adenocarcinoma, 2010–12
|
Colon tumours |
Rectal tumours |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Denmark | England | Norway | Sweden | Denmark | England | Norway | Sweden | ||
| Median follow-up time, years (IQR) | 2·5 (0·9–3·5) | 2·4 (0·7–3·5) | 2·5 (1·1–3·7) | 2·7 (1·4–3·7) | 2·7 (1·5–3·7) | 2·6 (1·4–3·6) | 2·8 (1·9–3·8) | 2·8 (1·8–3·8) | |
| 1-year net survival (95% CI) | |||||||||
| All stages | 80·3 (79·5–81·0) | 78·2 (77·9–78·5) | 80·9 (80·1–81·6) | 83·9 (83·3–84·5) | 85·5 (84·5–86·5) | 84·6 (84·2–85·0) | 87·4 (86·0–88·6) | 87·6 (86·7–88·5) | |
| Stage I | 97·1 (95·6–98·1) | 98·7 (97·8–99·2) | 98·2 (96·4–99·1) | 100 (100·0–100·0) | 98·0 (95·8–99·1) | 98·8 (98·2–99·1) | 98·4 (95·9–99·4) | 99·8 (99·6–99·9) | |
| Stage II | 94·5 (93·4–95·4) | 94·9 (94·6–95·3) | 95·5 (94·4–96·3) | 96·8 (96·1–97·4) | 95·3 (93·9–96·3) | 94·6 (93·8–95·3) | 99·8 (99·8–99·8) | 97·5 (96·1–98·4) | |
| Stage III | 87·8 (86·4–89·2) | 87·5 (87·1–88·0) | 89·3 (87·8–90·6) | 90·7 (89·7–91·6) | 90·0 (87·9–91·7) | 91·1 (90·4–91·8) | 93·9 (92·3–95·2) | 93·6 (92·1–94·8) | |
| Stage IV | 52·9 (51·3–54·5) | 48·4 (47·8–49·1) | 57·3 (55·4–59·1) | 51·9 (50·2–53·6) | 61·6 (59·3–63·9) | 60·0 (58·9–61·0) | 66·6 (63·8–69·2) | 61·5 (59·4–63·6) | |
| Unknown stage | 62·8 (60·2–65·4) | 62·2 (61·3–63·0) | 58·0 (55·0–60·8) | 78·9 (76·1–81·4) | 78·9 (75·9–81·6) | 72·7 (71·6–73·8) | 75·2 (71·8–78·2) | 83·1 (80·4–85·5) | |
| 2-year net survival (95% CI) | |||||||||
| All stages | 71·9 (71·0–72·8) | 69·9 (69·5–70·2) | 73·9 (73·0–74·8) | 76·7 (75·9–77·5) | 78·2 (76·9–79·4) | 76·2 (75·7–76·8) | 80·3 (78·6–81·8) | 79·8 (78·6–81·0) | |
| Stage I | 96·2 (94·3–97·5) | 98·2 (97·1–98·9) | 98·2 (96·4–99·1) | 99·5 (97·2–100·0) | 97·0 (93·9–98·6) | 97·8 (96·9–98·4) | 98·4 (95·9–99·4) | 99·8 (97·5–100·0) | |
| Stage II | 92·3 (90·9–93·5) | 92·7 (92·2–93·2) | 94·7 (93·4–95·7) | 95·3 (94·3–96·2) | 93·0 (91·1–94·5) | 90·3 (89·2–91·3) | 98·9 (98·0–99·4) | 95·1 (93·2–96·4) | |
| Stage III | 81·4 (79·6–83·1) | 80·1 (79·5–80·7) | 82·1 (80·2–83·8) | 84·0 (82·7–85·3) | 83·0 (80·2–85·4) | 82·9 (81·9–83·9) | 88·2 (85·7–90·3) | 86·8 (84·9–88·6) | |
| Stage IV | 34·4 (32·8–36·1) | 30·5 (29·9–31·1) | 41·9 (39·9–44·0) | 33·6 (31·8–35·3) | 42·4 (39·9–44·9) | 39·7 (38·6–40·8) | 49·6 (46·6–52·4) | 39·8 (37·7–42·0) | |
| Unknown stage | 53·2 (50·4–56·0) | 52·8 (51·9–53·8) | 49·8 (46·6–52·8) | 73·0 (69·8–75·9) | 72·0 (68·4–75·2) | 63·5 (62·1–64·7) | 64·2 (60·3–67·9) | 77·1 (73·9–79·9) | |
| 3-year net survival (95% CI) | |||||||||
| All stages | 65·7 (64·7–66·8) | 63·9 (63·5–64·3) | 69·5 (68·4–70·5) | 72·1 (71·2–73·0) | 72·5 (71·1–74·0) | 69·7 (69·1–70·3) | 75·0 (73·1–76·8) | 74·1 (72·7–75·4) | |
| Stage I | 95·6 (93·4–97·0) | 97·8 (96·6–98·6) | 98·2 (96·4–99·1) | 99·3 (96·0–99·9) | 96·3 (92·4–98·2) | 96·9 (95·6–97·8) | 98·4 (95·9–99·4) | 99·3 (95·7–99·9) | |
| Stage II | 90·6 (88·9–92·0) | 91·0 (90·4–91·5) | 94·3 (93·0–95·4) | 94·1 (92·8–95·1) | 91·2 (88·8–93·1) | 86·4 (85·0–87·6) | 94·1 (91·5–96·0) | 92·9 (90·8–94·6) | |
| Stage III | 76·3 (74·1–78·4) | 74·1 (73·3–74·8) | 76·3 (74·0–78·4) | 78·4 (76·8–79·9) | 77·2 (73·9–80·1) | 75·5 (74·2–76·7) | 83·4 (80·1–86·1) | 80·6 (78·2–82·7) | |
| Stage IV | 23·5 (21·9–25·1) | 20·5 (19·9–21·1) | 33·0 (31·0–35·1) | 23·7 (22·0–25·3) | 30·4 (28·0–32·9) | 27·1 (26·0–28·2) | 38·5 (35·5–41·4) | 26·7 (24·7–28·8) | |
| Unknown stage | 47·4 (44·5–50·2) | 47·0 (45·9–48·0) | 45·2 (42·0–48·4) | 69·7 (66·3–72·9) | 67·3 (63·3–70·9) | 57·2 (55·8–58·6) | 56·7 (52·4–60·8) | 73·2 (69·8–76·3) | |